Skip to content
Review

Abstract 9083: Efficacy and Safety of High-Flow Nasal Cannula vs. Other Oxygenation Techniques in Cardiogenic Pulmonary Edema: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Background: Cardiogenic pulmonary edema is a common cause of acute respiratory failure and requires rapid respiratory support to improve oxygenation and breathing. Noninvasive ventilation has traditionally been used first-line in this setting; however, high-flow nasal cannula (HFNC) has emerged as a potentially better-tolerated alternative. Evidence comparing HFNC with other ventilation techniques remains limited. Research Question: To compare the efficacy and safety of HFNC versus other oxygenation techniques in patients with cardiogenic pulmonary edema through a systematic review and meta-analysis of randomized controlled trials. Methods: Public databases including EMBASE, PubMed, Cochrane Library, and ClinicalTrials.gov were searched from inception to May 2026 for randomized controlled trials comparing HFNC with other oxygenation techniques. Primary outcomes included respiratory rate at 60 minutes, oxygen saturation at 15 minutes, pH at 60 minutes, intubation within 24 hours, and 7-day mortality. Secondary outcomes included heart rate and mean arterial pressure at 60 minutes. Random-effects inverse-variance and Mantel-Haenszel models calculated pooled mean differences or odds ratios with 95% confidence intervals (CI). A p-value of <0.05 was deemed significant. Results: Five studies comprising 779 patients were included. HFNC significantly improved oxygen saturation at 15 minutes (MD: 2.53%; 95% CI: 0.15 to 4.91), but did not significantly reduce respiratory rate at 60 minutes (MD: –1.76 breaths/min; 95% CI: –3.87 to 0.35) or alter pH (MD: –0.02; 95% CI: –0.06 to 0.03). HFNC modestly reduced heart rate (MD: –2.54 bpm; 95% CI: –4.59 to –0.48), while mean arterial pressure was similar (MD: –0.50 mmHg; 95% CI: –4.12 to 3.13). Intubation within 24 hours (OR: 0.60; 95% CI: 0.11 to 3.15) and 7-day mortality (OR: 0.62; 95% CI: 0.12 to 3.13) did not differ significantly. Subgroup analysis demonstrated significant between-subgroup heterogeneity by comparator type. Conclusion: HFNC improves early oxygenation and modestly lowers heart rate, but does not significantly reduce intubation or mortality. Comparator type may influence respiratory-rate response, warranting further larger trials.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.